Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 5/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447659 | 0.95 | CCR1 (0.39) | F10EPHX2CCR1FPR2ALDH1A1 | |
| SCHEMBL3447685 | 0.93 | FPR2 (0.45) | F10EPHX2MEN1KMT2AFPR2 | |
| SCHEMBL3450668 | 0.93 | CCR1 (0.44) | F10EPHX2LMNACCR1FPR2 | |
| SCHEMBL3451848 | 0.93 | CCR1 (0.44) | F10EPHX2LMNACCR1FPR2 | |
| SCHEMBL3449677 | 0.93 | CCR1 (0.44) | F10EPHX2LMNACCR1FPR2 | |
| SCHEMBL3452013 | 0.93 | F10 (0.38) | CCR3F10EPHX2LMNACCR1 | |
| SCHEMBL3451846 | 0.91 | EPHX2 (0.44) | CCR3EPHX2 | |
| SCHEMBL3449248 | 0.91 | FPR2 (0.43) | F10MEN1KMT2ACCR1FPR2 | |
| SCHEMBL3449116 | 0.91 | MEN1 (0.40) | CCR3EPHX2MEN1KMT2ALMNA | |
| SCHEMBL3452485 | 0.90 | FAAH (0.35) | FAAHF10EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CCR3 3188/4885FAAH 2986/4885HTR1E 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.